US FDA Accepts Sun Pharma’s NDA for Dry Eye Candidate

December 29, 2017: By Jon Swedien

The US FDA has accepted Sun Pharmaceutical Industries’ new drug application (NDA) for OTX-101 for dry eye disease, the company announced Dec. 27.

OTX-101 (cyclosporine A, ophthalmic solution) 0.09% is a novel nanomicellar formulation in a clear, preservative-free aqueous solution. The NDA was filed by Sun Pharma’s wholly owned subsidiary, Sun Ophthalmics.

If approved, OTX-101 would be the third pharmaceutical drug for dry eye disease approved in the US market.

In a 12-week, multicenter, randomized, double-masked Phase III confirmatory study, 744 dry eye patients were treated either with OTX-101 or its vehicle. After the 12 weeks of treatment, OTX-101 showed statistically significant improvement in the primary endpoint, Schirmer’s score (p<0.0001), compared with vehicle, Sun Pharma said.

The study demonstrated the potential of OTX-101 to offer patients improved tear production with faster onset of action, Sun Pharma said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023